Efficacy and economic evaluation of pilocarpine in treating radiation-induced xerostomia

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 9, 2003, Pages 1489-1497

  Taylor, Samuel E ^a  

^a BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

Dry mouth; Pilocarpine; Radiation; Salivary stimulants; Xerostomia

Indexed keywords

AMIFOSTINE; AMPHOTERICIN B; ANETHOLE TRITHIONE; ATROPINE; BETHANECHOL; CARBACHOL; CARBOXYMETHYLCELLULOSE; CEVIMELINE; CHLORHEXIDINE; CLOTRIMAZOLE; FLUCONAZOLE; FLUORIDE; FLUORIDE SODIUM; FLUORIDE VARNISH; GLUCOSE OXIDASE; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; HYDROXYMETHYLCELLULOSE; ITRACONAZOLE; KETOCONAZOLE; LACTOPEROXIDASE; LYSOZYME; MACLEANS 40+; MOUTHKOTE; NYSTATIN; ORALBALANCE; PERFECT CHOICE; PILOCARPINE; PLANT EXTRACT; PREVIDENT; PREVIDENT 5000 PLUS; SALIVA SUBSTITUTE; STANNOUS FLUORIDE; STOMACH MUCIN; THERA FLUR N; UNCLASSIFIED DRUG; UNINDEXED DRUG; YERBA EXTRACT;

BACTERIAL INFECTION; CHILL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DENTAL HEALTH; DENTITION; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; FLUSHING; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPOTENSION; INDIVIDUALIZATION; MOUTH HYGIENE; MYCOSIS; NAUSEA; NAUSEA AND VOMITING; PALLIATIVE THERAPY; PREDICTION; QUALITY OF LIFE; RADIATION SICKNESS; REVIEW; RHINITIS; SALIVART; SALIVATION; SUPERINFECTION; SWEATING; SYMPTOMATOLOGY; URINARY TRACT DISEASE; VISUAL IMPAIRMENT; XEROSTOMIA;

ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; FLUORIDES; HEAD AND NECK NEOPLASMS; HUMANS; MUSCARINIC AGONISTS; PILOCARPINE; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY; SALIVA, ARTIFICIAL; XEROSTOMIA;

EID: 0141740270     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.9.1489     Document Type: Review

References (58)

1. DREIZEN S, DALY TE, DRANE JB, BROWN LR: Oral complications of cancer radiotherapy. Postgrad. Med. (1977) 61:85-92.
2. MAKKONEN TA, NORDMAN E: Estimation of long-term salivary gland damage induced by radiotherapy. Acta Oncol. (1987) 26:307-312.
3. FRANK RM, HERDLY J, PHILIPPE E: Acquired dental defects and salivary gland lesions after irradiation for carcinoma. J. Amer. Dent. Assoc. (1965) 70:878-883.
4. CHAUSHU G, ITZKOVITZ-CHAUSHU S, YEFENOF E, SLAVIN S, OR R, GARFUNKEL AA: A longitudinal followup of salivary secretion in bone marrow transplant patients. Oral Surg. Oral Med. Oral Path. Oral Radiol. Endod. (1995) 79(2):164-169.
5. DENS F, BOOGAERTS M, BOUTE P et al.: Caries-related salivary microorganisms and salivary flow rate in bone marrow recipients. Oral Surg. Oral Med. Oral Path. Oral Radiol. Endod. (1996) 81(1):38-43.
6. SCHNEYER LH: Source of resting mixed saliva ofman. J. Appl. Physiol. (1956) 9:79-81.
7. DAWES C: Factors influencing salivary flow rate and composition. In: Saliva and Oral Health (2nd edn), Edgar WM, O'Mullane DM (Eds), Br. Dent. J., London (1996).
8. FRANZEN L, FUNEGARD U, ERICSON T, HENRIKSSON R: Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. Eur. J. Cancer (1992) 28(2-3):457-462.
9. LESLIE MD, DISCHE S: Parotid gland function following accelerated and conventionally fractionated radiotherapy. Radiother. Oncol. (1991) 22(2):133-139.
10. COOPER JS, FU K, MARKS J, SILVERMAN S: Late effects of radiation therapy in the head and neck region. Internat. J. Rad. Oncol. Biol. Phys. (1995) 31(5):1141-1164.
11. TSUJII H: Quantitative dose-response analysis of salivary function following radiotherapy using sequential RI-sialography. Internat. J. Rad. Oncol. Biol. Phys. (1985) 11(9):1603-1612.
12. LEVINE MJ: Development of artificial salivas. Crit. Rev. Oral Biol. Med. (1993) 4(3-4):279-286.
13. HILLMAN JD: Principles of microbial ecology and their application to xerostomia-associated opportunistic infections of the oral cavity. Adv. Dent. Res. (1996) 10(1):66-68.
14. RAMIREZ-AMADOR V, SILVERMAN S Jr, MAYER P, TYLER M, QUIVEY J: Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy. Oral Surg. Oral Med. Oral Path. Oral Radiol. Endod. (1997) 94(2):149-153.
15. FOX PC: Management of dry mouth. Dent. Clin. North Am. (1997) 41(4):863-875.
16. MADEYA ML: Oral complications from cancer therapy: part 1-pathophysiology and secondary complications. Oncol. Nurs. Forum (1996) 23(5):801-807.
17. GREENSPAN D: Xerostomia: diagnosis and management. Oncology (Huntingt.) (1996) 10(3 Suppl.):7-11.
18. RHODUS NL, MOLLER K, COLBY S, BEREUTER J: Dysphagia in patients with three different etiologies of salivary gland dysfunction. Ear Nose Throat J. (1995) 74(1):39-42; 45-48.
19. BACKSTROM I, FUNEGARD U, ANDERSSON I, FRANZEN L, JOHANSSON I: Dietary intake in head and neck irradiated patients with permanent dry mouth symptoms. Eur. J. Cancer. Oral Oncol. (1995) 31B(4):253-257.
20. RHODUS NL, MOLLER K, COLBY S, BEREUTER J: Articulatory speech performance in patients with salivary gland dysfunction: a pilot study. Quintessence Int. (1995) 26(11):805-810.
21. EISBRUCH A, SHIP JA, MARTEL MK et al.: Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Internat. J. Rad. Oncol. Biol. Phys. (1996) 36(2):469-480.
22. EISBRUCH A, KIM HM, TERRELL JE, MARSH LH, DAWSON LA, SHIP JA: Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50(3):695-704.
23. CHAO KS, DEASY JO, MARKMAN J et al.: A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int. J. Radiat. Oncol. Biol, Phys. (2001) 49(4):907-916.
24. RUDAT V, MEYER J, MOMM F et al.: Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. (2000) 48(5):1339-1343.
25. BRIZEL DM, WASSERMAN TH, HENKE M et al.: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. (2000) 18(19):3339-3345.
26. KOUKOURAKIS MI, KYRIAS G, KAKOLYRIS S et al.: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized Phase II study. J. Clin. Oncol. (2000) 18(11):2226-2233.
27. WARDE P, O'SULLIVAN B, ASLANIDISBACKSTROM I, FUNEGARD U, ANDERSSON I, FRANZEN L, JOHANSSON IJ et al.: A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54(1):9-13.
28. LAJTMAN Z, KRAJINA Z, KRPAN D, VINCELJ J, BORCIC V, POPOVIC-KOVACIC J: Pilocarpine in the prevention of postirradiation xerostomia. Acta Med. Croatica (2000) 54(2):65-67.
29. ZIMMERMAN RP, MARK RJ, TRAN LM, JUILLARD GF: Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. Internat. J. Rad. Oncol. Biol. Phys. (1997) 37(3):571-575.
30. VALDEZ IH, WOLFF A, ATKINSON JC, MACYNSKI AA, FOX PC: Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer (1993) 71(5):1848-1851.
31. JHA N, SEIKALY H, HARRIS J et al.: Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother. Oncol. (2003) 66:238-289.
32. REUTHER T, SCHUSTER T, MENDE U, KÜBLER A: Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients - a report of a thirty year retrospective review. Internat. J. Oral Maxillofacial Surg. (2003) 32:289-295.
33. CRAMER CK, EPSTEIN JB, SHEPS SB, SCHECHTER MT, BUSSER JR: Modified Delphi survey for decision analysis for prophylaxis of post-radiation osteonecrosis. Oral Oncol (Huntingt.) (2002) 38(6):574-583.
34. NATIONAL INSTITUTES OF HEALTH (US): Diagnosis and management of dental caries throughtout life. NIH Consens. Statement (2001) 18(1):1-23.
35. ANDREWS N, GRIFFITHS C: Dental complications of head and neck radiotherapy: part 2. Aust. Dent. J. (2001) 46(3):174-182.
36. AL-HASHIMI I: The management of Sjögren's syndrome in dental practice. J. Am. Dent. Assoc. (2001) 132:1409-1417.
37. DE ROSSI SS, GREENBERG MS: Intraoral contact allergy: a literature review and case reports. J. Am. Dent. Assoc. (1998) 129(10):1435-1441.
38. RIEKE JW, HAFERMANN MD, JOHNSON JT et al.: Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Internat. J. Oncol. Biol. Phys. (1995) 31(3):661-669.
39. LEVEQUE FG, MONTGOMERY M, POTTER D et al.: A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J. Clin. Oncol. (1993) 11(6):1124-1131.
40. JOHNSON JT, FERRETTI GA, NETHERY WJ et al.: Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer [see comments]. N. Engl. J. Med. (1993) 329(6):390-395.
41. VIVINO FB, AL-HASHIMI I, KHAN Z et al.: Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch. Intern. Med. (1999) 159(2):174-181.
42. SCARANTINO CW, LEVEQUE FG, SCOTT CB et al.: A Phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&N) cancer patients. RTOG 9709. Proc. Am. Soc. Clin. Oncol. (2001) 20:225a.
43. FISHER J, SCOTT C, SCARANTINO CW et al.: Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer - RTOG 9709. Int. J. Radiat. Oncol. Biol. Phys. (2003) 56(3):832-836.
44. COOPER RA, COWAN RA, OWENS SE et al.: Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia? Eur. J. Nucl. Med. (1999) 26(3):220-225.
45. FOX PC, BUSCH KA, BAUM BJ: Subjective reports of xerostomia and objective measures of salivary gland performance. J. Amer. Dent. Assoc. (1987) 115(4):581-584.
46. NIEDERMEIER W, MATTHAEUS C, MEYER C, STAAR S, MULLER RP, SCHULZE HJ: Radiation-induced hyposalivation and its treatment with oral pilocarpine. Oral Surg. Oral Med. Oral Path. Oral Radiol. Endod. (1998) 86(5):541-549.
47. RHODUS NL: Oral pilocarpine HCI stimulates labial (minor) salivary gland flow in patients with Sjogren's syndrome. Oral Dis. (1997) 3(2):93-98.
48. O'CONNELL AC, PEARSON SK, BOWEN WH: Pilocarpine alters caries development in partially-desalivated rats. J. Dent. Res. (1994) 73(3):637-643.
49. CELLA DF. CHERIN EA: Quality of life during and after cancer treatment. Compr. Ther. (1988) 14(5):69-75.
50. BRENNAN MT, SHARIFF G, LOCKHART PB, FOXPC: Treatment of xerostomia: asystematic review of therapeutic trials. Dent. Clin. North Am. (2002) 46:847-856.
51. PETRONE D, CONDEMI JJ, FIFE R, GLUCK O, COHEN S, DALGIN P: A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. (2002) 46(3):748-754.
52. FIFE RS, CHASE WF, DORE RK et al.: Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch. Intern. Med. (2002) 162(11):1293-1300.
53. EPSTEIN JB, BURCHELL JL, EMERTON S, LE ND, SILVERMAN S Jr: A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. Oral Surg. Oral Med. Oral Pathol. (1994) 77(6):610-614.
54. JOENSUU H, BOSTROM P, MAKKONEN T: Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. Radiother. Oncol. (1993) 26(1):33-37.
55. ROSAS J, RAMOS-CASALS M, ENA J et al.: Usefalness of basal and pilocarpine-stimulated salivary flow in primary Sjogren's syndrome. Correlation with clinical, immunological and histological features. Rheumatology (2002) 41(6):670-675.
56. DENNY PC, DENNY PA, YIM MS: The effects of various secretagogues on the mucin content of pure submandibular salivas. J. Dent. Res. (1987) 66(5):1011-1015.
57. DAWSON LA, ANZAI Y, MARSH L et al.: Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. (2000) 46(5):1117-1126.
58. TAYLOR SE, MILLER EG: Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Proc. Soc. Exp. Biol. Med. (1999) 221(1):14-26.